Background: The impact of being overweight remains unclear in Asian populations that
Introduction
IgA nephropathy (IgAN) is the most frequent chronic glomerulonephritis and its prognosis is poor: about 15 to 40 percent of patients will eventually have end-stage kidney disease (ESKD) (1) . Since IgAN is a chronic glomerular disease and progresses gradually over the long term, additional factors may have a lot of influence on the prognosis.
Therefore, a more diversified treatment is needed.
Along with the development of metabolic syndrome analysis, more attention has been paid to the influence of obesity on chronic kidney disease (CKD). Bolignano et al. indicated that obesity is one of the independent risk factors for the development and progression of CKD (2) . Similarly, excessive body mass index (BMI) is reported as a risk factor for disease progression in IgAN patients in several studies (3) . On the other hand, there are ethnic differences in body size. In general, Asians are leaner than those of European origin. BMI cut-off points for obesity are different in Asian countries from those that the World Health Organization (WHO) has defined. In comparison with the guideline issued by the WHO, where obesity has been defined as BMI ≥ 30 kg/m (4), it is defined as ≥ 25 kg/m 2 in Korea and Japan, ≥ 27 kg/m 2 in Taiwan, and ≥ 28 kg/m 2 in China (5).
Moreover, Asians, including Japanese, are susceptible to the accumulation of visceral fat and are easy to develop type 2 diabetes and cardiovascular diseases, even with a BMI lower than 25 kg/m 2 (6, 7) . Despite this ethnic difference of body size, in most of studies about obesity using BMI, the BMI cut-off point was defined as 25 kg/m 2 . Since BMI of
Asian patients with CKD is often below 25 kg/m 2 , the importance of appropriate body size tends to be underestimated.
The impact of overweight on the progression of IgAN among lean Asian individuals is not sufficiently elucidated. In the present study, the authors analysed the anthropometric data of 193 Japanese IgAN patients with a follow-up period of more than five years to investigate the impact of high BMI on the progression of IgAN. 
Materials and methods

Patients
Treatment Protocol
For steroid pulse therapy, patients received intravenous methylprednisolone pulse therapy of 0.5 g/day for three consecutive days, followed by oral prednisolone at an initial dosage of 0.5mg/kg every other day for 6 months. The oral prednisolone was gradually tapered off every 2 months, as follows: 0.25 mg/kg, 0.125mg/kg, 0.0625 mg/kg and off.
The definition of 'aggressive therapy' is steroid therapy, including oral steroid and/or steroid pulse, and/or tonsillectomy (8) .
Biochemical assessment (clinical data)
All samples collected were from fasting subjects and were analyzed at the time of biopsy and the final observation at a single center (Juntendo University Hospital). BMI was calculated as weight in kilograms divided by the square of height in meters. (10) . UP and urinary creatinine were measured using a spot urine analysis to gain the UP to creatinine ratio. The median follow-up time after renal biopsy was five years. The levels of s-Cr, UP, and uRBCs after the renal biopsy were yearly compared after five years. We defined UP < 0.3 g/gCr as UP remission, uRBCs < 5 /HPF as uRBCs remission, and both UP < 0.3 g/gCr and uRBCs < 5/HPF as complete remission (8) .
Morphometric analysis
Paraffin-embedded sections were routinely stained with hematoxylin and eosin, periodic acid-Schiff, Masson's trichrome, and periodic acid-silver methenamine. The activity and severity were graded using the Japanese classification of IgAN (11) . Staining for IgG, IgA, IgM, C3c, and C1q on freshly frozen renal tissue was performed using a corresponding fluorescence isothiocyanate-conjugated anti-sera (Dako, Copenhagen, Denmark). Renal tissues were immediately fixed in a 2 % osmium and phosphate buffer saline for two hours, dehydrogenated by increasing the concentration of alcohol, and then embedded in Epok 812 (Oken-syoji, Tokyo, Japan).
Statistical analysis
Data are expressed as mean ± standard deviation (SD) of the mean or as percentages.
Normality of each continuous variable was initially examined using the Bartlett test. The clinical parameters of the three groups were compared using an analysis of variance (ANOVA) with Bonferroni's multiple comparison test for normally distributed continuous variables or Kruskal-Wallis test with post-hoc for non-normally distributed variables.
Categorical variables were also compared using a Chi-square test or Fisher extract test. A Spearman's correlation coefficient by rank was performed to examine the relationship between BMI and clinical data. The cumulative probability of remission of UP and uRBCs were compared using the log-rank test. The multivariate Cox regression analysis was used to assess the determinants of remission of proteinuria. Statistical significance was considered as p < 0.05. All statistical analyses were performed by using GraphPad Prism 6, version 6.0c (GraphPad, San Diego, CA, USA) or the JMP 9.0.1 (SAS Institute Inc., Cary, NC, USA) software program.
Results
Distribution of BMI and age
The distribution peak of BMI shifted to the left. The number of patients whose BMI was greater than 25 was only 15% of the total subjects ( Figure 1 ). The bars of the figure are divided by age categories. Those who have a small BMI tended to be young. 
Comparison of clinical parameters at the time of renal biopsy
Correlation between BMI and clinical variables in all patients
BMI was significantly correlated with UA, TG, C4, Hct, Hb, C3, HDL-c, s-Cr, sBP, dBP, CRP, eGFR, LDL-c, age, CH50, TC, and SUN (Table 2) .
Pathological findings
In the light microscopic findings, there were no significant differences among the three groups (Table 3) , though Group M and Group O tended to have arteriosclerotic findings. In the immunofluorescence findings, there were fewer patients with depositions of IgA, IgG, and IgM in Group O.
Treatment
Several treatment strategies were chosen during the follow-up period, and there was a significant difference (Table 4) . In Group O, tonsillectomy and steroid pulse was performed less frequently. Renin-angiotensin system inhibitors and calcium channel blockers were prescribed more frequently.
Comparison of the incidence rate of remission of UP and uRBCs
The remission of UP and uRBCs was compared among the three groups. Because the change of eGFR was scarce during the observation period (data not shown), the remission rate of uRBCs and UP was compared. Remission of UP was significantly delayed in Group O over five years ( Figure 2 ). Especially in the first 10 months, the UP of approximately half of the patients in Group M and Group L disappeared. On the other hand, only 20 % of the patients in Group O showed a UP remission. In order to ascertain whether the low remission rate of the patients in Group O was because fewer patients were given aggressive therapy, the three groups were divided into six groups by the presence or absence of aggressive therapy (Figure 3 ). In patients with aggressive therapy, UP remission was similar among the three groups. With aggressive therapy, UP in about half of the patients in each group disappeared within only 10 months. In patients without aggressive therapy, UP remission in Group O was significantly delayed.
Comparison of the clinical findings at the final observation
In order to evaluate not only urinary findings and renal function, but also the change of body size and clinical data, we collected the clinical data and BMI of patients at their last follow-up period. Consequently, 80 of the 193 patients were able to have their BMI checked at the final observation. The data of all patients treated at our faculty with a renal biopsy were not collected because there were patients who dropped out from the outpatient clinic because of urinary remission or because of a move. There were two patients who needed renal replacement therapy (RRT) among the patients in Group M and one patient in Group L during the observation period. All of them had not been given aggressive therapy (data not shown).
In the patients without aggressive therapy in Group O, BMI, TG, UA, and systolic BP were higher, and HDL-c was lower (Table 4) . On the other hand, in the patients with aggressive therapy in Group O, TC and LDL-c were a little higher than the other groups.
There were no patients who developed diabetes, cataract, bone abnormalities during the observation period and their FPG and HbA1c were similar to those at renal biopsy. In all groups, BMI had not changed significantly during the observation period. s-Cr in patients without aggressive therapy in Group M was higher than that in the other groups.
Discussion
The most important finding of this study was that in IgAN, patients with high BMI achieved UP remission slower than other groups and that might lead to a worsening of their prognosis. In the patients without aggressive therapy, the differences among the three groups were more evident, whereas with aggressive therapy, the differences disappeared.
These results indicate that in IgAN high BMI is an important factor that interferes in the remission of proteinuria, especially in the absence of aggressive treatment. Thus, we
should not leave patients with high BMI untreated.
In this study, 'aggressive therapy' includes steroid oral administration, steroid pulse therapy, tonsillectomy, or a combination of them. Pozzi reported the effectiveness and safety of steroid pulse therapy (12) . A combination of tonsillectomy and steroid pulse therapy was developed in Japan (13) . In Japan, UP > 0.5 g/day and eGFR > 60 mL/min/1.73m 2 is a provisionary criterion for tonsillectomy combined with steroid pulse therapy (14) , but the adequate adaptation of these aggressive therapies has not been clearly defined. In our study, we observed that the patients with aggressive therapy in Group O did not have any major side effects. Therefore, the result suggests that the adaptation of aggressive therapy on patients with obesity should be extended.
Three mechanisms are indicated as influences of overweight on the progression of IgA nephropathy. First, patients with overweight have metabolic-related disorders like dyslipidemia, hyperuricemia, and hypertension, which lead to insulin-resistance and finally, accelerated arteriosclerosis. In this study, metabolic parameters were much worse in the patients with higher BMI and showed a significant correlation with BMI. Each of them is also pointed out to have an effect on the progress of IgAN patients (15) (16) (17) (18) . Secondly, when overweight accompanies IgAN, pathological changes may have an effect on the prognosis. Tanaka et al. (19) reported that non-diabetic obese patients with IgAN showed significantly increased proteinuria, accompanied by glomerular basement membrane thickening and glomerulomegaly, like obesity-related glomerulopathy (20) . Thirdly, recent studies indicate that overweight itself likely has effects on renal injury through various hemodynamic and nonhemodynamic mechanisms of adipocytes.
As to the third mechanism, recently, adipocytes have been revealed to be not only storage cells but also the production site for a variety of hormones and proinflammatory molecules that may contribute to progressive renal damage (21) . Metabolic disorders are well known to be associated with inflammation (22) . Although leptin is famous as an adipocytokine, the degeneration product of C3 is also considered to be one type of adipocytokine. In the present study, the concentration of serum C3 in Group O was significantly higher than that in the other groups, although they remained within the normal limit. We also found a slight elevation of CRP, which is considered to reflect chronic, low-grade inflammation due to overweight. A complement cascade is activated within the sites of connective tissues and atherosclerotic lesions (23) . The authors have previously demonstrated that male patients with metabolic syndrome showed higher concentrations of serum C3, and C3 is closely related to insulin resistance (24) . In IgAN patients, we also have indicated that the serum C3 level is closely related to nutritional status, metabolic syndrome, and the prognosis of the patients (25). Kim et al. (26) reported that a low level of serum C3 and mesangial C3 deposition were independent risk factors for poor renal outcome in patients with IgAN. In this study, high BMI had a strong relation with inflammation and the degeneration product of C3 may also correlate with BMI as one type of adipocytokine through artherosclerosis. We need further analysis to clarify the association of serum C3 and artherogenic change.
Body size has racial difference. In this study, we did not define the cut-off point for obesity and divided them equally into three groups according to order of BMI.
Consequently, the border between Group M and Group O became 23. Our results implied that IgAN might progress faster in Japanese patients with a BMI between 23 and BMI 25 because of overweight. Similarly, there is increasing evidence of an emerging high prevalence of type 2 diabetes and increased cardiovascular risk factors in parts of Asian countries where the average BMI is below the cut-off point of 25 kg/m 2 (6,7). Asians generally have a higher percentage of body fat than white people of the same age, sex, and BMI (27) . Therefore, when we evaluate Asian patients with renal disease, defining a smaller BMI cut-off point for obesity may be better. Although we were not able to show the ideal BMI in this study, our results indicated that patients with IgAN should target a smaller BMI in order to improve the prognosis of IgAN.
Several researchers reported that in elderly and non-Caucasian populations, the relationship between BMI and body fatness might be different as compared with a younger Caucasian population (28) . Despite the patients in our study being Japanese, their metabolic factors were significantly correlated with BMI. We consider that the reason is that the individuals in our study were comparably young. In our study, there were young patients with high BMI. As some researchers have noted that being overweight in early adulthood is strongly associated with declined kidney function in later life (29, 30) , reducing weight may be important especially for young patients with obesity.
This study has several limitations. First, waist circumference (WC) was not measured.
Recently, waist circumference and the waist to hip ratio (WHR), which can estimate abdominal fat more precisely, are preferably used. It would be advisable to check not only BMI but also the WC and WHR of patients with IgAN regularly in the future. Second, there were patients who dropped out from our outpatient clinic. Some patients moved and others might suffer ESKD and underwent renal RRT. Third, this study is a retrospective study and we could not control the selection bias for treatment.
In conclusion, in Japanese patients with IgAN, even slightly high BMI seems to be a risk factor for progress. They should reduce their body weight and improve their metabolic factors. 
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